13 de diciembre de 2019
  • Jueves, 12 de Diciembre
  • 27 de febrero de 2009

    Prasugrel Showed Significant Reduction in Cardiovascular Events in High-Risk Heart Attack Patients Undergoing Stenting C

    This press release contains certain forward-looking statements about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the compound will receive regulatory approval, that the regulatory approval will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.

    Plavix and Iscover are registered trademarks of Sanofi-Aventis Corp.


    1 Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine. November 2007;357:2001-15.

    2 British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008, http://www.ehnheart.org/files/statistics%202008%20web-161229..., Accessed December 9, 2008.

    3 American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. http://www.americanheart.org/downloadable/heart/120008200524... 008.final.pdf . Accessed December 9, 2008.

    4 WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease. http://www.webmd.com/heartdisease/guide/heart-disease-corona... . Accessed December 9, 27 Feb. (Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO ) -

    Carole Copeland (OUS), +1-317-277-3661 (office), +1-317-610-6196 (cell), Tammy Hull (U.S.A.), +1-317-651-9116 (office), +1-317-614-5132 (cell), both of Eli Lilly and Company; Kim Wix, Daiichi Sankyo (U.S.A.), +1-973-695-8338 (office), +1-908-656-5447 (cell), Shigemichi Kondo, Daiichi Sankyo (Tokyo), +81-3-6225-1126 (office); Photo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO